(Circulation. 2000;101:454.)
© 2000 American Heart Association, Inc.
Current Perspective |
Delivery Strategies to Achieve Therapeutic Myocardial Angiogenesis
From the Cardiovascular Research Foundation, Washington Hospital Center, Washington DC.
Abstract—The use of recombinant genes or growth factors to enhance myocardial collateral blood vessel function may represent a new approach to the treatment of cardiovascular disease. Proof of concept has been demonstrated in animal models of myocardial ischemia, and clinical trials are underway. Currently, it is unknown which is the safest and most effective delivery strategy to induce clinically important therapeutic angiogenic responses in ischemic myocardium. Most strategies for transcatheter delivery of angiogenic factors have used an intracoronary route, which may have limitations because of imprecise localization of genes or proteins and systemic delivery to noncardiac tissue. The effect of direct intraoperative intramyocardial injection of angiogenic factors on collateral function has been reported in experimental models, and angiogenesis is being studied after direct intramyocardial injection of angiogenic peptides or plasmid vectors during open heart surgery in patients. Catheter-based transendocardial injection of angiogenic factors may provide equivalent benefit without the need for surgery. Intrapericardial delivery of angiogenic factors may offer a theoretical advantage of prolonged exposure of either coronary or myocardial tissue to the administered drug as result of a reservoir function of the pericardium. In this article, we review the different modes of administration for therapeutic myocardial angiogenesis therapy.
Key Words: myocardium • gene therapy • angiogenesis
This article has been cited by other articles:
 |
|
 |
|
  J. Kobulnik, M. A. Kuliszewski, D. J. Stewart, J. R. Lindner, and H. Leong-Poi Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1735 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Leong-Poi, M. A. Kuliszewski, M. Lekas, M. Sibbald, K. Teichert-Kuliszewska, A. L. Klibanov, D. J. Stewart, and J. R. Lindner Therapeutic Arteriogenesis by Ultrasound-Mediated VEGF165 Plasmid Gene Delivery to Chronically Ischemic Skeletal Muscle Circ. Res., August 3, 2007; 101(3): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Krombach, J. G. Pfeffer, S. Kinzel, M. Katoh, R. W. Gunther, and A. Buecker MR-guided Percutaneous Intramyocardial Injection with an MR-compatible Catheter: Feasibility and Changes in T1 Values after Injection of Extracellular Contrast Medium in Pigs Radiology, May 1, 2005; 235(2): 487 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hosaka, H. Koyama, T. Kushibiki, Y. Tabata, N. Nishiyama, T. Miyata, H. Shigematsu, T. Takato, and H. Nagawa Gelatin Hydrogel Microspheres Enable Pinpoint Delivery of Basic Fibroblast Growth Factor for the Development of Functional Collateral Vessels Circulation, November 23, 2004; 110(21): 3322 - 3328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raake, G. von Degenfeld, R. Hinkel, R. Vachenauer, T. Sandner, S. Beller, M. Andrees, C. Kupatt, G. Schuler, and P. Boekstegers Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: Comparison with surgical and percutaneous intramyocardial gene delivery J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1124 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. von Degenfeld, P. Raake, C. Kupatt, C. Lebherz, R. Hinkel, F. J. Gildehaus, W. Munzing, A. Kranz, J. Waltenberger, M. Simoes, et al. Selective Pressure-Regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1120 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Roguin, A. Avivi, S. Nitecki, I. Rubinstein, N. S. Levy, Z. A. Abassi, M. B. Resnick, O. Lache, M. Melamed-Frank, A. Joel, et al. Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat Spalax ehrenbergi VEGF PNAS, April 15, 2003; 100(8): 4644 - 4648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.C Felmeden, A.D Blann, and G.Y.H Lip Angiogenesis: basic pathophysiology and implications for disease Eur. Heart J., April 1, 2003; 24(7): 586 - 603. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Voskuil, N. van Royen, I. E. Hoefer, R. Seidler, B. D. Guth, C. Bode, W. Schaper, J. J. Piek, and I. R. Buschmann Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1 Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1422 - H1428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Strauer and R. Kornowski Stem Cell Therapy in Perspective Circulation, February 25, 2003; 107(7): 929 - 934. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Poller, H. Fechner, M. Noutsias, C. Tschoepe, M. Pauschinger, and H.-P. Schultheiss The molecular basis of cardiotropic viral infections Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I18 - I30. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. R. Hermans, H. van Essen, H. A. J. Struijker-Boudier, R. M. Johnson, F. Theeuwes, and J. F. M. Smits Pharmacokinetic Advantage of Intrapericardially Applied Substances in the Rat J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 672 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Menasche and M Desnos Cardiac reparation: fixing the heart with cells, new vessels and genes Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D73 - D81. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Azrin Angiogenesis, protein and gene delivery Br. Med. Bull., October 1, 2001; 59(1): 211 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.V Patil, E Nikolsky, M Boulos, E Grenadier, and R Beyar Multivessel coronary artery disease: current revascularization strategies Eur. Heart J., July 2, 2001; 22(14): 1183 - 1197. [PDF]
|
|
|
|
|
|
M. Simons Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi? Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H1923 - H1927. [Full Text] [PDF]
|
|
|
|
 |
|
 N. van Royen, J. J. Piek, I. Buschmann, I. Hoefer, M. Voskuil, and W. Schaper Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease Cardiovasc Res, February 16, 2001; 49(3): 543 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Pantely and J. M. Porter Therapeutic angiogenesis: time for the next phase J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1245 - 1247. [Full Text] [PDF]
|
|
|
|
|
|
Z.-S. Jiang, R. R. Padua, H. Ju, B. W. Doble, Y. Jin, J. Hao, P. A. Cattini, I. M. C. Dixon, and E. Kardami Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H1071 - H1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Villanueva, J. A. Abraham, G. F. Schreiner, M. Csikari, D. Fischer, J. D. Mills, U. Schellenberger, B. J. Koci, and J. S. Lee Myocardial Contrast Echocardiography Can Be Used to Assess the Microvascular Response to Vascular Endothelial Growth Factor-121 Circulation, February 12, 2002; 105(6): 759 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simons, B. H. Annex, R. J. Laham, N. Kleiman, T. Henry, H. Dauerman, J. E. Udelson, E. V. Gervino, M. Pike, M.J. Whitehouse, et al. Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial Circulation, February 19, 2002; 105(7): 788 - 793. [Abstract] [Full Text] [PDF]
|
|